GI-BCT SIGNED
Disruptive imaging technology for accurate and painless breast cancer diagnosis
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0GI-BCT project word cloud
Explore the words cloud of the GI-BCT project. It provides you a very rough idea of what is the project "GI-BCT" about.
Project "GI-BCT" data sheet
The following table provides information about the project.
| Coordinator |
GRATXRAY AG
Organization address contact info |
| Coordinator Country | Switzerland [CH] |
| Project website | https://www.gratxray.com/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-05-01 to 2018-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | GRATXRAY AG | CH (VILLIGEN) | coordinator | 50˙000.00 |
Map
Project objective
Breast cancer is the most prevalent form of cancer in women, as 1 in 9 women are affected and 1 in 30 will die from the disease. Early detection is essential to reduce the mortality, thus countries have established routing screening programs. The problem is that main screening procedure of mammography is painful for patients, produces high rate of false positives for women with dense breast tissue, provides limited contrast, low-resolution and poor tissue discrimination properties. False positives lead to performing unnecessary therapeutic procedures. Also cancer in dense breasts is missed out by mammography, lowering survival outcomes when discovered in later stage. GratXray is entering the 3,56 BEUR size breast imaging market with our disruptive grating interferometry-based breast computed tomography – GI-BCT technology. GI-BCT will provide painless, efficient and precise breast cancer imaging. The breast will be scanned in its natural state in 3D, without compression and contrast agents, yielding images with a much higher contrast and better resolution. Thus saving €1,85B in healthcare costs in Europe and US by avoiding recalls, €640 000 from machinery costs for breast centers and potentially save treatment costs in the amount of €95 000 per patient. We have worked for the past 15 years in GI-BCT research and have a solid patent portfolio of 8 granted patents. Currently, we have demonstrated our technology in operational environment, and we are ready to start first clinical trials in 2D with the goal to make first sales in Q1 2021. We have formed a team that combines strong scientific, industry and user know-how. We estimate that a further investment of €5M and 3 years is required to reach the commercialization stage. We estimate that in year 6 we have hired 50 employees, sold 59 systems per year, have 207 service contracts, revenue of 68 MEUR, net profits of 21 MEUR and reach ROI of 4 (400%).
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GI-BCT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GI-BCT" are provided by the European Opendata Portal: CORDIS opendata.